Plain-English translation of NCT04969731 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After pancreatic cancer surgery, doctors typically give patients chemotherapy to help prevent cancer from coming back. This trial is testing whether adding —a treatment designed to boost your immune system—alongside standard chemotherapy works better than chemotherapy alone. The goal is to see if the combination helps you stay cancer-free longer.
Pancreatic cancer is very serious, and even after surgery, there's a high risk it will return. Standard chemotherapy after surgery helps, but researchers want to know if this medication can improve those results by helping your body's immune system fight any remaining cancer cells more effectively.
You likely qualify if…
You likely don't qualify if…
You would receive 6 cycles of standard chemotherapy over about 24 weeks, with three doses each cycle. If randomly assigned to the combination group, you would also receive the new immune therapy 16 times over 60 weeks—starting with weekly injections, then spacing them out to every other week, then monthly, then every 8 weeks. You'll have regular blood tests and clinic visits to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
South Korea
Phase
Large-scale testing
Sponsor
GC Cell Corporation
Enrollment target
~408 participants
Started
September 2021
Primary completion
December 2026
Age range
19 Years – 80 Years
Last updated on clinicaltrials.gov in November 2021.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.